It is established that aminoguanidine (AG) is a metabolism-based inactivator of the three major isoforms of nitric-oxide synthase. AG is thought to be of potential use in diseases, such as diabetes, where pathological overproduction of NO is implicated. We show here that during the inactivation of neuronal nitric-oxide synthase (nNOS) by AG that the prosthetic heme is altered, in part, to dissociable and protein-bound adducts. The protein-bound heme adduct is the result of cross-linking of the heme to residues in the oxygenase domain of nNOS. The dissociable heme product is unstable and reverts back to heme upon isolation. The alteration of the heme is concomitant with the loss in the ability to form the ferrous-CO complex of nNOS and accounts for at least two-thirds of the activity loss. Studies with [ 14 C]AG indicate that alteration of the protein, in part on the reductase domain of nNOS, also occurs but at low levels. Thus, heme alteration appears to be the major cause of nNOS inactivation. The elucidation of the mechanism of inactivation of nNOS will likely lead to a better understanding of the in vivo effects of NOS inhibitors such as AG.
are cytochrome P-450-like hemoprotein enzymes that catalyze the conversion of L-arginine to citrulline and nitric oxide by a process that requires NADPH and molecular oxygen (1) (2) (3) (4) . NOSs are bidomain in structure with an oxygenase domain, which contains the cysteine residue that is coordinated to the prosthetic heme as well as the tetrahydrobiopterin binding site, and a reductase domain, which contains the binding sites for FMN, FAD, and NADPH (5) . For the neuronal and endothelial isoforms, the activity of the enzyme is regulated by calcium and calmodulin, which binds to a site between the oxygenase and reductase domains. In the case of the macrophage or inducible NOS (iNOS), the calmodulin is bound very tightly and is not regulated by physiological levels of calcium (6) .
The isoform-selective inhibition of NOS has been of intense interest because of the various physiological and pathological actions of nitric oxide caused by the three isoforms (for reviews see Refs. [7] [8] [9] [10] [11] . Our laboratory has focused on the inhibition of neuronal NOS (nNOS) by guanidine drugs (12) . Aminoguanidine (AG) is structurally one of the simplest of these drugs containing a guanidino moiety and a hydrazine group. AG is thought to be of potential use in diabetes (11, 13) , and it was first reported by Corbett et al. (14) to inhibit iNOS in a selective manner. The selectivity for iNOS has been confirmed in various models (11, 15) , although in some studies the selectivity appears to be limited (16, 17) . More recently, it was shown that AG is an isoform-selective mechanism-based inactivator of iNOS in vitro, although the constitutive NOS in GH 3 pituitary cells and that in endothelial cells could also be inactivated (18) . Diaminoguanidine, which is structurally related to AG, is also a mechanism-based inactivator of all three isoforms of NOS, although it exhibits less selectivity for iNOS (19) . The mechanism by which AG causes the inactivation of NOS is not known.
In studies with the use of [ 14 C]AG, it has been shown that inactivation of iNOS causes radiolabel to be associated in part with iNOS protein (20) . In the same study, the fluorescence caused by the heme was not altered by AG treatment of iNOS, indicating that the prosthetic heme was not destroyed. HPLC analysis of iNOS treated with [ 14 C]AG showed radiolabel associated with a peak that eluted with "near identity" to heme, and the authors suggest that this was an altered heme product, but this product was not further characterized (20) . Moreover, it is not clear how much of the prosthetic heme is altered in relation to iNOS inactivation from these studies. More recently, similar to the findings on iNOS, the inactivation of nNOS by AG has been found to occur without changes in the heme fluorescence and to lead to irreversible binding of [ 14 C]AG to the protein (21) . Thus, it appears that AG can alter the heme or protein of NOS, but the role for either of these processes in the inactivation has not been demonstrated
In the current study, we have sought to define the mechanism by which AG inactivates recombinant nNOS. We demonstrated that AG causes the alteration of the prosthetic heme in part to a dissociable adduct as well as to a protein-bound adduct, which was primarily the result of heme binding irreversibly to a site(s) on the oxygenase domain. The alteration of the heme was concomitant to the loss in the ability to form the ferrous-CO complex and appears to be the major cause for the loss of enzyme activity. Inactivation of nNOS with [
14 C]AG gave radiolabel associated with the dissociable heme product as well as radiolabel irreversibly bound to the protein primarily at a site(s) on the reductase domain of nNOS. These studies further our understanding of the mechanisms involved in the inactivation of nNOS and may aid in predicting the action of NOS inhibitors in vivo.
EXPERIMENTAL PROCEDURES

Materials
The affinity-purified rabbit IgG against brain NOS used for immunoblotting nNOS was from Transduction Laboratories (Lexington, KY). Aminoguanidine, trypsin (tosylphenylalanyl chloromethyl ketonetreated, bovine pancreas), trypsin inhibitor (Type 1S, soybean), glucose-6-phosphate, glucose-6-phosphate dehydrogenase, myoglobin (horse heart), cytochrome c (Type III, horse heart), NADP ϩ , and NADPH were purchased from Sigma.
14 C-Labeled aminoguanidine (53 mCi/mmol) was purchased from Moravek Biochemicals, Inc. (Brea, CA). (6R)-5,6,7,8-Tetrahydro-L-biopterin (tetrahydrobiopterin) was purchased from Dr. Schirck's Laboratory (Jona, Switzerland). Tris(2-carboxyethyl)phosphine and Super Signal enhanced chemiluminescence reagent were from Pierce.
Methods
Purification of nNOS-nNOS was overexpressed in Sf9 insect cells as described previously (22) . Oxyhemoglobin (25 M) was added as a source of heme during expression. Cells were harvested and suspended in 1 volume of 10 mM Hepes, pH 7.5, containing 320 mM sucrose, 100 M EDTA, 0.1 mM dithiothreitol, 10 g/ml trypsin inhibitor, 100 M leupeptin, 0.5 M pepstatin A, 2 g/ml of aprotinin, 3 mM phenylmethanesulfonyl fluoride, and 10 M tetrahydrobiopterin, and the suspended cells were ruptured by Dounce homogenization. Lysates from infected Sf9 cells (8 ϫ 10 9 ) were centrifuged at 100,000 ϫ g for 1 h. The supernatant fraction was loaded onto a 2Ј5Ј-ADP Sepharose column (8 ml) , and the nNOS was affinity purified as described (5) , except that 10 mM 2Ј-AMP in high salt buffer was used to elute the protein. The nNOS-containing fraction was concentrated and dialyzed against 50 mM Tris-HCl, pH 7.4, containing 100 mM NaCl, 10% glycerol, 0.1 mM EDTA, 0.1 mM dithiothreitol, and 100 M tetrahydrobiopterin with the use of a ProDicon and a 100-kDa cut-off membrane. The concentrated sample was stored at Ϫ80°C.
Treatment of nNOS with AG and NOS Activity Assay-nNOS (0.5 M) was added to a "first reaction mixture" of 40 mM potassium phosphate, pH 7.4, containing 1.0 mM NADPH, 0.2 mM CaCl 2 , 100 unit/ml superoxide dismutase, 25 unit/ml catalase, 40 g/ml calmodulin, 10 M tetrahydrobiopterin, and AG at various concentrations in a total volume of 150 l at room temperature. Aliquots (20 l) of the reaction mixture were transferred to an "oxyhemoglobin assay mixture" containing 200 M CaCl 2 , 100 M NADPH, 100 M L-arginine, 100 M tetrahydrobiopterin, 100 units/ml catalase, 10 g/ml calmodulin, and 16 M oxyhemoglobin in a total volume of 200 l of 50 mM potassium phosphate, pH 7.4. The mixture was incubated at 37°C, and the rate of NO-mediated oxidation of oxyhemoglobin was monitored by measuring the absorbance at 401-411 nm with a microtiter plate reader (SpectraMax Plus, Molecular Devices, Sunnydale, CA) as described previously (23) . Where indicated, the concentration of nNOS in the first reaction mixture was changed, and the amount of calmodulin was proportionally increased.
SDS Polyacrylamide Gel Electrophoresis-The first reaction mixtures were added to an equal volume of sample buffer containing 5% SDS, 20% glycerol, 40 mM dithiothreitol, and 0.02% bromphenol blue in 125 mM Tris-HCl, pH 6.8, and boiled for 2 min. For studies where the chemiluminescence of the heme was measured, 100 mM Tris(2-carboxyethyl)phosphine replaced dithiothreitol in the sample buffer, and the samples were treated at 50°C for 10 min instead of boiling (24). Samples were subjected to electrophoresis on 7% SDS polyacrylamide gels (10 ϫ 8 cm), using the discontinuous buffer system described by Laemmli (25) and transferred to nitrocellulose membranes (0.2 m; Bio-Rad). The protein-bound heme was detected with the use of enhanced chemiluminescence reagent and X-OMAT film (Eastman Kodak Co., Rochester, NY) as described previously (24). The radioisotope bound to proteins on dried gels was detected with the use of a PhosphorImager (model 445 SI, Molecular Dynamics, Sunnyvale, CA).
Trypsin Treatment of nNOS-nNOS (3 M) was treated with AG in the first reaction mixture. An aliquot (150 l) of the reaction mixture was added to 75 l of a 0.1 mM Tris-Cl, pH 7.6, solution containing 20 mM EGTA and trypsin (2000 milliunits/ml). After incubation at room temperature, an equal volume of gel sample buffer containing soybean trypsin inhibitor (20 g/ml) was added. An aliquot (40 l) was analyzed with the use of SDS-PAGE as described above.
HPLC-HPLC was performed with the use of a Waters 600S controller, 717 plus autosampler, and 996 photodiode array detector (Waters Corp., Milford, MA). First reaction mixtures were injected onto an HPLC column (C18 Vydac 5 m, 0.21 ϫ 15 cm) equilibrated with 65% solvent A (0.1% trifluoroacetic acid) and 35% solvent B (0.1% trifluoroacetic acid in acetonitrile) at a flow rate of 0.3 ml/min. After 15 min, a linear gradient was run to 100% solvent B over 10 min. Absorbance at 220 and 400 nm was monitored. Myoglobin was used as a standard. In studies with radioactive AG, an on-line radiochemical detector (Radiomatic 500TR, Packard, Downers Grove, IL) was used to detect the radiolabeled products.
P-450 Assay-The ferrous-carbonyl complex was determined from the CO difference spectrum of the dithionite-reduced protein with the use of an extinction coefficient of 91 mM Ϫ1 (3, 26) . The difference spectrum was measured with the use of an Aminco-DW2 spectrophotometer modified with the OLIS-DW2 operating system.
Cytochrome c Reductase Assay-Aliquots (5 l) of the first reaction mixture were added to a mixture containing 0.2 mM NADPH, 0.1 mg/ml bovine serum albumin, 0.2 mM CaCl 2 , 4 M FAD, 4 M FMN, 40 g/ml calmodulin, 10 units/ml catalase, 100 units/ml superoxide dismutase, and 500 M cytochrome c in a total volume of 195 l of 40 mM potassium phosphate, pH 7.4, and incubated at 30°C. The NADPH-dependent reduction of cytochrome c was monitored over time at 550 nm with a SpectraMax Plus microtiter plate reader (Molecular Devices). An extinction coefficient of 21 mM Ϫ1 cm Ϫ1 was used along with a correction for the pathlength as described by Molecular Devices. The initial rate was determined from the linear portion of the time-dependent change in absorbance. Fig. 1A , AG caused a concentration-and time-dependent loss of nNOS activity. This inhibition process was saturable and could be described by an apparent dissociation constant for the initial reversible AG-enzyme complex (K i ) and an inactivation constant (k inact ) of 54.6 M and 0.046 min Ϫ1 , respectively ( whereby a substrate is metabolized to a reactive intermediate that covalently alters nNOS and inactivates the enzyme (27) . These findings are also consistent with that established for the AG-mediated inactivation of the constitutive NOS found in GH 3 pituitary cells, except that the reported K i and k inact are 830 M and 0.25 min Ϫ1 , respectively (18) . The reason for the greater than 10-fold difference in the K i is not known, although IC 50 values of 41 M have been reported for the AG-mediated inhibition of nNOS found in GH 3 pituitary cells (28) . Fig. 2A shows the HPLC profile of nNOS treated with AG in the absence of calmodulin. The major fraction with absorption at 220 nm corresponds to heme-depleted apo-nNOS (NOS) and the major fraction with absorption at 400 nm corresponds to native heme (Heme), which dissociates from the protein under the acidic conditions of the chromatography. As shown in Fig.  2B , treatment of nNOS with AG in the presence of calmodulin gave a loss in the peak area for native heme and the appearance of two new peaks with absorption at 400 nm (peak I and peak II). The profile at 220 nm showed the nNOS peak as well as three additional peaks, which are from the calmodulin preparation. As will be described in more detail below, peak I corresponds to a dissociable heme adduct, whereas peak II, which co-eluted with apo-nNOS, corresponds to an altered heme product irreversibly bound to the protein. The potential differences in absorptivity of the products precludes accurate quantitation by HPLC.
RESULTS
Effect of Aminoguanidine on Neuronal NOS Activity-As shown in
AG Causes the Alteration of the Prosthetic Heme of nNOS-
Characterization of the Loss of Heme-As shown in Fig. 3 , the loss of heme observed on the HPLC profile at 400 nm was quantified and compared with the loss of nNOS activity. The loss of heme and activity occurred only when AG was incubated with nNOS in the presence of calmodulin (Fig. 3 , compare AG with AG-CAM). Moreover, L-arginine could protect from the heme loss as well as from inactivation by AG (AG ϩ ARG). Thus, like the activity loss observed above, the heme loss was dependent on calmodulin and attenuated by the natural substrate. As shown in Fig. 4A , the loss in heme and nNOS activity were both time-dependent. During the first 10 min, the amount of the heme that was altered appeared to approximate the enzyme inactivation, whereas after 15 min of incubation there was greater activity loss without much change in the amount of heme. The time course for the formation of the products corresponding to peak I (ϫ) and peak II (f) are shown in Fig. 4B . As shown in Fig. 5B , the differences in the extent of the loss of heme (HM) and activity (Act) at 15 min were statistically significant (p Ͻ 0.05). Thus, at short incubation times the heme loss accounted for nearly all of the activity loss, whereas at longer incubation times the extent of heme loss accounted for approximately two-thirds of the activity loss. As shown in Fig.  5B , the cytochrome c reductase activity (R) was only slightly decreased, again supporting the notion that heme loss is the major cause of inactivation. We have determined that the loss of heme was concomitant to a loss in the ability of nNOS to form the ferrous-CO complex (Fig. 5B , compare HM with Fe-CO), a confirmation that heme loss results in dysfunctional enzyme. As shown in Fig. 5A , the loss in P-450 did not result in the formation of substantial amounts of P-420.
Characterization of the Dissociable Heme Product-As shown above, the alteration of the heme resulted, in part, in the formation of a dissociable heme product corresponding to peak I, which can be detected by its absorbance at 400 nm (Fig. 6C) . In studies with the use of 150 M [
14 C]AG, the inactivation of nNOS led to the association of radiolabel to peak I as well as to fractions containing nNOS protein (Fig. 6B) . The radiolabel was not detected in these fractions when calmodulin is absent during the treatment of nNOS (Fig. 6A) . Based on the amount of radioactivity associated with peak I, there was approximately 0.05 mol of radiolabeled product/mol of nNOS monomer. Similarly, there was 0.10 mol of radiolabel product/mol of nNOS found in the protein containing fraction. The stoichiometry of labeling on peak I and the protein was increased to 0.1 and 0.6 mol/mol of nNOS monomer, respectively, when nNOS was treated with 500 M AG for 20 min (data not shown).
The spectra of fractions that correspond to heme, peak I, and peak II were determined by on-line diode array analysis (Fig.  7) . All three samples were found to have the characteristic Soret absorbance of porphyrin compounds. The Soret of peak I was found to be red-shifted to 405 nm in comparison to that found for heme at 398 nm, whereas the Soret for peak II appeared to be similar to heme. We isolated the compound corresponding to peak I for subsequent mass spectral analysis but found the product to be unstable after isolation. Analysis of the isolated sample corresponding to peak I on the HPLC resulted in detection of native heme as determined by retention time and diode array analysis. This was also confirmed by mass spectrometry (data not shown). Thus, although the compound corresponding to peak I was stable in the reaction mixture, after isolation the compound reverted back to native heme. As shown in Fig. 8 , a peak that corresponds by retention time to peak I found in HPLC profiles of AG-treated nNOS was also found in reaction mixtures of nNOS treated with diaminoguanidine, which differs from AG by the addition of an amino group. The Soret for peak I detected in the reaction mixture with diaminoguanidine was also red-shifted to 405 nm (Fig. 8,  inset) .
Characterization of the Protein-bound Heme Adducts-The compounds corresponding to peak II appeared by HPLC to be protein-bound heme adducts. This was further verified by a recently developed method for specific detection of proteinbound heme adducts after SDS-PAGE by enhanced chemiluminescence (24). The specificity for protein-bound heme is based on the ability of SDS-PAGE to separate heme that is irreversibly bound to protein from native heme that is dissociated from the protein and runs at the dye front (24). As shown in Fig. 9A , nNOS that was treated with AG in the presence of calmodulin (lane 1) gave an intense chemiluminescence signal at a mass of approximately 160 kDa, which corresponds to the monomer of nNOS. The sample treated with AG but without calmodulin (lane 2) gave a very faint chemiluminescence signal. This is consistent with the absence of peak II in the HPLC profile of this sample. There was an increase in the chemiluminescence signal after treatment of nNOS with calmodulin alone (lane 3), indicating that autoinactivation can also give rise to the formation of protein-bound heme adducts, although clearly AG enhanced the formation of these adducts over this control level. To further define the site of adduct formation of heme with nNOS, we utilized limited tryptic digestion of nNOS. Salerno et al. (29) have shown that limited trypsinolysis of nNOS gives rise to a 77-kDa fragment, which represents the carboxylterminal reductase domain, and a 85-kDa fragment, which represents the amino-terminal oxygenase domain. As shown in 
FIG. 7.
Absorption spectra of heme and altered heme products corresponding to peak I and peak II. The absorption spectra of heme (short and long dashes), peak I (short dashes), and peak II (solid line) were obtained by on-line diode array analysis of the HPLC effluent. The Soret maximum for heme, peak I, and peak II was observed at 398, 405, and 398, respectively. Characterization of the 14 C-Labeled Protein Adduct-As shown above, HPLC analysis of nNOS treated with 150 M [ 14 C]AG for 20 min revealed that radioisotope was associated with the nNOS protein containing fractions with a stoichiometry of 0.1 mol of 14 C-labeled compound/mol of nNOS. That nNOS was specifically labeled was further verified by SDS-PAGE analysis (Fig. 10A) . As shown in Fig. 10A , the radiolabeling was greatly enhanced in the reaction mixture containing calmodulin (compare lanes 1 and 2) . There were greater amounts of radioisotope found on nNOS after treatment for 60 min, although there was an increase in the control samples as well (compare lanes 3 and 4) . In that there is no greater activity loss because of AG from 20 to 60 min under these conditions, the increase in radioisotope associated with nNOS over this period must not be related to the inactivation process. Thus, we further characterized the binding of radiolabel to nNOS after a 20-min treatment with [ 14 C]AG. As shown in Fig. 10B , the [ 14 C]AG-inactivated nNOS was treated with trypsin for 10 min to give two major Coomassie-stained peptide fragments at 85 and 77 kDa (left panel, compare lanes 1 and 2) . The most intense radioactive band was at 77 kDa, which corresponds to a peptide in the reductase domain (right panel, compare lanes 1 and 2). Smaller amounts of radioactivity were found in the 85-kDa band, which corresponds to the oxygenase domain, as well as a diffuse band of lower molecular mass that was more pronounced after a 30-min trypsin hydrolysis (lane 3). DISCUSSION We have determined that the mechanism of inactivation of nNOS by AG was due in large part to the alteration of the prosthetic heme moiety. This loss of the heme could account for at least two-thirds of the activity loss and perhaps even more FIG. 8 . HPLC profile of diaminoguanidine-treated nNOS. nNOS (1.3 M) was incubated with 100 M diaminoguanidine in the first reaction mixture for 60 min, and an aliquot (50 l) was analyzed by HPLC as described under "Experimental Procedures." The HPLC profile at 400 nm for diaminoguanidine-treated nNOS (dashed line) and AG-treated nNOS (solid line). Inset, absorption spectra of peak I from AG-treated nNOS (solid line) and diaminoguanidine-treated nNOS (dashed line). The Soret maximum for both products was observed at 405 nm. during the initial phases of the inactivation reaction. The AGmediated alteration of heme was time-and metabolism-dependent and attenuated by the presence of the natural substrate, L-arginine. These findings were highly similar to that found for the loss in enzyme activity. The loss in heme gave a concomitant loss in the ability to form the ferrous-CO complex, indicating that the altered heme products were unable to function as P-450 catalysts, again confirming that heme loss was responsible for the activity loss. The loss of heme or ferrous carbonyl complex has been shown to occur during the suicide inactivation by (31) , and vinyl-NIO (32) . L-N 6 -(1-Iminoethyl)lysine was found in one study to cause the loss of heme (20) , whereas another did not (33) . Only in the case of NIO has the altered heme product been found (30) .
In the current study, the heme was found to be altered, in part, to a dissociable and a protein-bound heme adduct. This is the first report of a protein-bound heme adduct of NOS, although examples of this reaction have been established for myoglobin (34, 35) , hemoglobin (36) , and cytochrome P-450 (37, 38) . A recently described enhanced chemiluminescence assay (24) was used to establish that the heme was predominantly bound to a site on the oxygenase domain. The chemiluminescence assay detects the peroxidase activity of the protein-bound heme adduct and indicates that the heme bound to the protein is intact and redox active.
The current study also demonstrated the formation of an intact heme product that can be dissociated from the protein under acidic conditions. The radioisotope studies have further indicated that the dissociable adduct likely contains a carbon atom derived from AG. The dissociable heme adduct was found to be unstable and to revert to native heme during isolation. Taken together, the dissociable heme product may be a tight reversible complex of an AG metabolite with heme or a covalently altered heme that can chemically breakdown to give native heme. One potential AG metabolite is a carbon radical formed from the oxidation of the hydrazine, analogous to that found for the reaction of hemoproteins with aryl-and alkylhydrazines (39, 40) . In fact, the reaction of nNOS with phenyldiazene gives rise to an iron phenyl complex with heme (41) . The formation of a carbon radical intermediate would be consistent with the observation that a highly similar dissociable heme product was formed from diaminoguanidine, which can be oxidized to give the same carbon radical intermediate as that for AG.
The finding that intact protein-bound and dissociable heme adducts are formed for nNOS is in accord with the report that nNOS and iNOS are inactivated by AG by a process that does not change the inherent fluorescence caused by the heme prosthetic group of the protein (20, 21) . The AG-mediated inactivation of nNOS to form intact heme adducts is in contrast to that found for NIO-mediated inactivation of iNOS where biliverdin is formed (30) . The formation of the dissociable heme adduct for nNOS in our study is in accord with the observation by Bryk and Wolff (20) that after treatment of iNOS with [
14 C]AG the radiolabel is found associated with an HPLC fraction containing native heme. This can be explained by the inability of the dissociable heme product to be separated from the native heme under the conditions employed by Bryk and Wolff (20) . Thus, it is likely that nNOS and iNOS are inactivated by similar mechanisms. In the current study on nNOS, we were able to resolve the dissociable heme product from heme and directly address the role of heme alteration in the inactivation process.
The inactivation of iNOS with [ 14 C]AG was found to give 0.63 mol of 14 C label/mol of iNOS (20) . More recently, a stoichiometry of 0.8 mol of 14 C label/mol of nNOS was determined for the inactivation of nNOS (21) . Moreover, based on this stoichiometry and the lack of change in the heme fluorescence of the inactivated nNOS, Bryk et al. (21) concluded that the inactivation by AG was due to covalent alteration of the protein. This differs from our observations and conclusions, in part, because of the following two reasons. First, the lack of change in heme fluorescence cannot be interpreted as the lack of heme alteration because the modified heme products that were found in our current study also fluoresce. Second, Bryk et al. (21) measured the binding of [ 14 C]AG to nNOS after treatment for 24 h. We found that radiolabeling of the nNOS protein occurs at a stoichiometry of 0.1 mol/mol of nNOS after treatment for 20 min but that the stoichiometry can increase to 0.6 mol/mol of nNOS after longer incubation periods. This greater binding, however, is not related to the inactivation event, which occurs over a shorter time period. In addition, even under conditions where nNOS was radiolabeled with a stoichiometry of 0.6 mol/ mol of nNOS, more than two-thirds of the inactivation was still due to the heme loss (Fig. 3) . Therefore, we conclude that the radiolabel bound to the protein likely plays a minor role in the inactivation process. The radiolabeling occurred to a much greater extent when nNOS was treated in the presence of calmodulin and indicates that a reactive metabolite is formed that covalently modifies the protein. It remains to be determined whether the reactive metabolite is the same as that responsible for the heme alteration. Moreover, tryptic mapping studies showed that the radiolabel binding occurs in large part to the reductase domain with some binding to the oxygenase domain. The mechanism for the cause of the activity loss by protein alteration is not known. The mechanism for inactivation of nNOS by covalent alteration of the protein may involve multiple mechanisms including destabilizing the active homodimer or interfering with the electron flow from reductase to the heme.
NMA causes a substantial alteration of the prosthetic heme that appears to be the major mechanism for inactivation of iNOS (31) . In the same study, experiments with 14 C-labeled NMA show that radiolabel is found associated with the iNOS protein with a stoichiometry of 0.1 mol/mol of NOS monomer. Thus, AG may be similar to NMA in that multiple mechanisms account for the loss of activity, with heme alteration being the major factor. The alterations of nNOS described here may be biologically important because suicide inactivated nNOS is selectively recognized by the proteosome and processed for degradation (42) . In the case of liver microsomal P-450 cytochromes, the crosslinking of the heme prosthetic group to the protein appears to be an important determinant in recognition by the proteosome (43, 44) . Moreover, the formation of dissociable heme adducts (44) or "heme stripping" to form apoprotein (45, 46) or covalent alteration of the protein (47) all fail to enhance proteolysis with liver microsomal P-450 cytochromes. The current study shows for the first time that nNOS can form heme-protein crosslinked adducts similar to that found for liver microsomal P-450 cytochromes. Thus, the current findings may aid in future studies on the elucidation of the nature of the alteration that triggers nNOS for proteosomal processing and degradation.
